New York City's Metropolitan Museum of Art said on Wednesday that it will be donated from the US Sackler family, made rich by the production of opioids.
The billionaire family owns Purdue Pharma, a company that manufactures opioids like OxyContin ̵
The company has allegations that they are downsizing about abuse and addiction to wider use.
The Met's move follows a similar wave of other galleries.
The National Portrait Gallery and the Tate Galleries in London, and the Solomon R Guggenheim Museum in New York have already sought to distance themselves from the controversial art patrons.
"The museum takes a position of gratitude and respects those who support us, but on occasion, we feel it is necessary to step away from gifts that are not in the public interest, or in our institution's interest," said Daniel H Weiss, the president of the Met, according to the New York Times. "That's what we're doing here."
Mr. Weiss said the museum will not remove the family's name from the Sackler Wing, home to the Temple of Dendur and one of the Met's most popular attractions.
The decades-old relationship between the museum and the Sackler family.
The New York Times published in 1978 news release announces the dedication of the Sackler Wing, which costs $ 9.5m (£ 8.48m) to build, approximately $ 36 million in today's dollars.
In March, Purdue Pharma reached a $ 270m settlement in lawsuit which claimed its opioids contributed to the deaths of thousands.
The lawsuit filed by Oklahoma claimed that in order to persuade doctors to prescribe their painkillers, Purdue, and Other companies such as Johnson & Johnson and Teva Pharmaceutical, allegedly decided to "falsely downplay the risk of opioid addiction" and "overstate" the benefits of their drugs to treat a wide range of conditions.
The deal is the first Purdue has struck amid some 2,000 other lawsuits linked to its painkiller OxyContin.
The companies deny the claims.
Posted on the Sackler trust website in March, chair of the trust Dame Theresa Sackler wrote that the family would "temporarily pause all new philanthropic giving" in the UK because of the heightened scrutiny on Purdue Pharma.
"This is what they are doing," she wrote.